Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma …
JCH Yang, MH Schuler, N Yamamoto, KJ O'Byrne… - 2012 - ascopubs.org
LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …
JCH Yang, YL Wu, M Schuler, M Sebastian… - The lancet …, 2015 - thelancet.com
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer …
T Ninomiya, N Nogami, T Kozuki, D Harada, T Kubo… - Lung Cancer, 2018 - Elsevier
Objective In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase …
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
LV Sequist, JCH Yang, N Yamamoto… - Journal of clinical …, 2013 - ascopubs.org
Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR …
8016 Background: A is an oral, irreversible, ErbB Family Blocker, blocking signaling from
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in …
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in …
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
CH Huang, JS Ju, TH Chiu, ACC Huang… - … Journal of Cancer, 2022 - Wiley Online Library
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
相关搜索
- lux lung japanese patients
- egfr mutations japanese patients
- lux lung egfr mutations
- subgroup analysis japanese patients
- lux lung subgroup analysis
- egfr mutations subgroup analysis
- egfr mutations afatinib and bevacizumab
- gefitinib in patients lung cancer
- afatinib and bevacizumab lung cancer
- lung adenocarcinoma pemetrexed in patients
- egfr mutations lung cancer
- lux lung gefitinib in patients
- egfr mutations lung adenocarcinoma
- egfr mutations pemetrexed in patients